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YbcL of Uropathogenic Escherichia coli Suppresses Transepithelial
Neutrophil Migration
Megan E. Lau,a Jennifer A. Loughman,a and David A. Hunstada,b
Departments of Pediatricsa and Molecular Microbiology,b Washington University School of Medicine, St. Louis, Missouri, USA
Uropathogenic Escherichia coli (UPEC) strains suppress the acute inflammatory response in the urinary tract to ensure access to
the intracellular uroepithelial niche that supports the propagation of infection. Our understanding of this initial cross talk be-
tween host and pathogen is incomplete. Here we report the identification of a previously uncharacterized periplasmic protein,
YbcL, encoded by UPEC that contributes to immunemodulation in the urinary tract by suppressing acute neutrophil migration.
In contrast to wild-type UPEC, an isogenic strain lacking ybcL expression (UTI89ybcL) failed to suppress transepithelial poly-
morphonuclear leukocyte (PMN) migration in vitro, a defect complemented by expressing ybcL episomally. YbcL homologs are
present in many E. coli genomes; expression of the YbcL variant encoded by nonpathogenic E. coli K-12 strain MG1655
(YbcLMG) failed to complement the UTI89ybcL defect, whereas expression of the UPEC YbcL variant (YbcLUTI) in MG1655
conferred the capacity for suppressing PMNmigration. This phenotypic difference was due to a single amino acid difference
(V78T) between the two YbcL homologs, and a majority of clinical UPEC strains examined were found to encode the suppressive
YbcL variant. Purified YbcLUTI protein suppressed PMNmigration in response to live or killedMG1655, and YbcLUTI was de-
tected in the supernatant during UPEC infection of bladder epithelial cells or PMNs. Lastly, early PMN influx to murine bladder
tissue was augmented upon in vivo infection with UTI89ybcL compared with wild-type UPEC. Our findings demonstrate a
role for UPEC YbcL in suppression of the innate immune response during urinary tract infection.
Urinary tract infections (UTI) are among the most commonbacterial infections in the United States, resulting in over $2
billion in direct and indirect costs (11). Uncomplicated UTI pri-
marily afflict otherwise healthy women, though anatomical and
urodynamic abnormalities, genetic variation, and behavior can
predispose individuals to infection.Despite appropriate antibiotic
therapy, resolution is often short-lived, and recurrent UTI are a
major problem (25% of women experience recurrent infection
within 6 months of initial infection) (11). As the gastrointestinal
(GI) tract serves as a reservoir for uropathogenic bacteria, recur-
rent infections are typically thought to arise through reinoculation
of the urinary tract with fecal flora.However, recent investigations
have identified a bacterial reservoir within the bladder epithelium
that is refractory to antibiotic and immune clearance andmay also
contribute to recurrence (28, 31). The recent emergence of anti-
biotic-resistant isolates further complicates the effective treat-
ment of UTI (37).
The majority of community-onset UTI are caused by a hetero-
geneous group of uropathogenic Escherichia coli (UPEC) strains that
employ a variety of strategies to effectively colonize andpersistwithin
the urinary tract. This is evidenced by an array of disease manifesta-
tions, which include asymptomatic bacteriuria, acute and recurrent
cystitis, and pyelonephritis. Investigations using a murine model of
cystitis andUPEC isolateUTI89 have revealed a complex pathogenic
cascade that begins with bacterial binding and invasion of the super-
ficial umbrella cells of the bladder epithelium through type 1 pilus-
uroplakin interactions (24, 25, 38). Internalizedbacteria rapidlymul-
tiplywithin theepithelial cell cytoplasmto formintracellularbacterial
communities (IBCs) that are protected from themounting immune
response (2, 26). Expansion of the IBC and associated epithelial cell
rupture release UPEC to initiate binding and invasion events with
neighboring cells, leading to additional rounds of IBC formation and
propagating the infection (19). The importance of bacterial amplifi-
cation within the intracellular niche for UPEC pathogenesis is dem-
onstrated by the attenuation of UPEC mutants unable to form ma-
ture IBCs (1, 29), the conservation of IBC formation among clinical
UPEC isolates in multiple murine backgrounds (12), and the pres-
ence of IBCs in samples from human patients (30). Given the signif-
icance of the IBC, the events that precede bacterial invasion facilitat-
ing intracellular replication likely dictate disease outcome.
As the urinary tract is typically a sterile environment, the pro-
liferation of UPEC within the bladder elicits a robust inflamma-
tory response characterized by the production of cytokines and
chemokines and the recruitment of leukocytes, primarily poly-
morphonuclear leukocytes (PMN) or neutrophils, which are es-
sential for clearance of bacteria from the urinary tract (13). UPEC
strains have acquired mechanisms to modulate the innate im-
mune response during acute infection to access the intracellular
niche (reviewed in reference 17). Recent studies have demon-
strated inhibition of proinflammatory signaling pathways and at-
tenuated cytokine production by cultured bladder epithelial cells
during infection with UPEC relative to nonpathogenic E. coli (3,
15, 18, 20). Similarly, UPEC strains inhibit PMN functions such as
production of reactive oxygen species, phagocytosis, and che-
motaxis (9, 10, 23). Though bacterial effectors responsible for
some of these phenotypes have been identified in some UPEC
strains, the conservation of innate immune modulation (3, 15)
and the considerable genome plasticity amongUPEC strains (5, 6,
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33) suggest that additional mechanisms of immune modulation
exist.
In this study, we identified a previously uncharacterized bac-
terial protein, YbcL, that contributes to modulation of the host
immune response by UPEC during acute UTI. While both non-
pathogenic and uropathogenic E. coli strains encode YbcL ho-
mologs, only the uropathogenic variant, YbcLUTI, suppressed
PMN migration in an in vitro model of acute inflammation, de-
pendent upon a threonine at amino acid 78 (where the nonpatho-
genic allele encodes a valine). The suppressive phenotypewas con-
ferred upon the nonpathogenic strain E. coli K-12 MG1655 by
episomal expression of the YbcLUTI variant or by addition of pu-
rified YbcLUTI protein to the bacterial inoculum. Furthermore,
YbcLUTI was detected in the supernatant during UPEC infection
of bladder epithelial cells and PMN in vitro, and YbcLUTI sup-
pressed PMN migration to the bladder at early time points in a
murine cystitis model. Taken together, these results describe a
novel bacterial product that contributes to UPEC pathogenesis by
influencing the innate immune response in the urinary tract.
MATERIALS AND METHODS
Bacterial strains and culture.E. coli strainswere grown statically in Luria-
Bertani (LB) broth at 37°C for 18 h. Where indicated, chloramphenicol,
ampicillin, or isopropyl -D-1-thiogalactopyranoside (IPTG) was added
at 20g/ml, 100g/ml, or 100M, respectively. UPEC strain UTI89 was
isolated from a patient with cystitis (6), and MG1655 is a well-character-
ized K-12 laboratory strain that is type 1 piliated (4). Heat-killed bacterial
suspensions were generated by a 30-min incubation at 55°C, and an ali-
quot of the suspensionwas plated to confirmbacterial death. UTI89 ybcL::
cat (also denoted UTI89 ybcL) was created by linear transformation of
UTI89/pKM208 (27) with a fragment amplified from template plasmid
pKD3 (8) using the primers JLP266 and JLP267 (primer sequences are
given in Table 1); the deletion was verified by direct sequencing. For
complementation experiments, a plasmid encoding YbcL with a C-termi-
nal FLAG tag under the control of an IPTG-inducible promoter was con-
structed. The ybcL open reading frame (ORF) carried by UTI89 was am-
plified from genomic DNA using primers MEL23 and MEL24, with the
reverse primer containing the FLAG epitope sequence. The fragment was
digested with BamHI and XbaI and then ligated into pTRC99A (Ampr)
which had been similarly digested. Transformed clones of E. coli Top10
(Invitrogen) were selected on ampicillin plates and tested by colony PCR.
Accuracy of the resulting pYbcLUTI construct was confirmed by direct
sequencing. Using a similar strategy, ybcL carried by MG1655 was am-
plified using primers MEL62 and MEL24 and ligated into pTRC99A to
generate pYbcLMG. The QuikChange site-directed mutagenesis kit
(Stratagene) was used to generate point mutations at the ybcL codon
for residue 78. Primers MEL69 and MEL70 and template plasmid
pYbcLUTI were used to generate pYbcLUTI(T78V). Primers MEL237 and
MEL238 and template plasmid pYbcLUTI were used to generate
pYbcLUTI(T78A). Primers MEL67 and MEL68 and template plasmid
pYbcLMG were used to generate pYbcLMG(V78T). The expected muta-
tions were verified by direct sequencing.
Membrane-tethered YbcL variants were designed according to the
findings of Yamaguchi and colleagues (34). To tether YbcL to the bacterial
inner membrane (YbcLIM), we generated a fusion protein between NlpA
(an inner membrane lipoprotein) and the mature form of YbcL. Using
UTI89 genomicDNAas the template, code for the signal sequence and the
first 12 amino acids of NlpA as well as a region homologous to the N
terminus of YbcL was amplified by primers MEL286 and MEL287. Se-
quence encoding the mature form of YbcL, including a region homolo-
gous to NlpA, was amplified by primers MEL288 andMEL24. These PCR
products were annealed and extended by PCR, digested with BamHI and
XbaI, and ligated into pTRC99A. Using a similar approach, we generated
an NlpA-YbcL fusion protein that localized to the outer membrane
(YbcLOM) by mutating the second amino acid in NlpA from an aspartic
acid to a serine (34). Primers MEL286 and MEL289 were used to amplify
the NlpA product containing the amino acid mutation, and primers
MEL290 and MEL24 were used to amplify the YbcL product. The PCR
products were cloned into pTRC99A as described above. The two con-
structs were verified by direct sequencing. Equivalent expression of all
YbcL variants after IPTG induction was confirmed by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) andWestern blot
analysis of bacterial fractions.
Tissue culture. The 5637 bladder epithelial cell line (derived from a
bladder carcinoma; ATCCHTB-9) was obtained from the American Type
Culture Collection. Cells were cultured and experiments were conducted
in RPMI 1640 medium (Gibco) supplemented with 10% fetal bovine se-
rum (Sigma) at 37°C in a humidified atmosphere with 5% CO2 unless
otherwise noted. Preparation of inverted epithelial monolayers has been
previously described (23). Briefly,  105 5637 cells were seeded on an
TABLE 1 Primers used in this study
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inverted Transwell insert (0.33-cm2 polycarbonate membranes with
3-m diameter pores; Corning number 3472) and allowed to adhere to
the membrane for 16 h. Transwells were then moved to a 24-well plate
containing tissue culture medium, and additional medium was added to
the upper reservoir. Fresh medium was applied every 2 days until the
epithelial monolayers reached confluence, as assessed by impermeability
to liquid (21).
Human PMN isolation. In accordance with a protocol approved by
the Washington University Human Research Protection Office, PMN
were isolated from venous blood of healthy adult volunteers after verbal
consent was obtained. The isolation of human PMN from blood was
adapted from a previously published protocol (14). In short, erythrocyte
numbers were reduced by dextran sedimentation, contaminating im-
mune cells (other than PMN) were removed using a Ficoll density gradi-
ent (Ficoll-Paque Plus; GE Healthcare), and the remaining erythrocytes
were lysed hypotonically. PMN viability was99% as assessed by trypan
blue exclusion, and purity was 99% as determined by visualization of
nuclear morphology after staining (Hema3; Fisher Scientific). Purified
PMN were resuspended in RPMI 1640 medium (Gibco) to a concentra-
tion of 107 PMN/ml and used immediately.
Transepithelial PMN migration assay. Transepithelial PMN migra-
tion assays were conducted in accordance with previously published pro-
tocols (23). Briefly, Transwells with confluent 5637 monolayers were
washed three times in RPMI. Bacterial cells were washed in phosphate-
buffered saline (PBS) and diluted in RPMI. A bacterial inoculum of 6 
106 CFU/ml (a multiplicity of infection [MOI] of 40 CFU/cell) or an
equivalent volume of RPMI was applied to the apical sides of inverted
Transwells and incubated for 1 h at 37°C. The Transwells were then
righted into 24-well plates (Ultra Low Attachment plates; Corning num-
ber 3473) containing 0.6ml RPMI, and 106 PMNwere added to the upper
reservoir. After 1 h at 37°C, PMN in the lower reservoir were collected and
enumerated using a hemacytometer, and the number of PMN recruited
into the lower reservoir was normalized to input PMN.Data represent the
mean and standard deviation from at least three independent experi-
ments. Statistically significant differences were determined using an un-
paired Student’s t test.
To generate conditioned medium, 5637 cells grown to confluence in
15-cm dishes were infected with the indicated strains of E. coli at an MOI
of 40. After 1 h of incubation at 37°C, the supernatant was collected and
filter sterilized using syringe-driven filter units (0.22-m pore size; Milli-
pore). The filter-sterilized supernatant (conditioned medium) was used
as the inoculum and replaced 0.6 ml RPMI in the lower reservoir in the
transepithelial PMN migration assay. PMN migration in response to the
conditioned medium was assessed as described above.
YbcL localization by Western blotting. To mimic the transepithelial
PMN migration assay, 5637 cells or freshly isolated PMN were infected
with the indicated strains of E. coli at an MOI of 40 or 10, respectively.
After 1 h of incubation at 37°C, the supernatant was collected and the
eukaryotic cells were washed with PBS and lysed using 0.1%Triton X-100
containing protease inhibitors (Roche). The supernatant and cell lysate
samples were filter sterilized using syringe-driven filter units (0.22-m
pore size; Millipore), and protein was precipitated using 15% trichloro-
acetic acid (TCA) (Sigma). Samples were separated by SDS-PAGE using 4
to 20% precast gels (Bio-Rad) and transferred to polyvinylidene difluo-
ride (PVDF)membranes (Millipore). After blocking with 2% nonfat milk
plus 2% bovine serum albumin (BSA) (Sigma), blots were probed with
mouse anti-FLAG antibody (1:1,000; Sigma) followed by goat anti-mouse
IgG antibody (1:2,000; Sigma) and were developed using Tropix CDP-
Star (Applied Biosystems).
Sequencing of ybcL alleles in clinical isolates. A collection of 74
UPEC isolates, including strains from women with acute cystitis, recur-
rent cystitis, asymptomatic bacteriuria, or pyelonephritis, was obtained
from Scott Hultgren (6, 12, 30). Chromosomal DNA was isolated from
each UPEC strain using the Wizard genomic DNA purification kit (Pro-
mega) according to the manufacturer’s instructions. Primers MEL231
and MEL232 were designed to bind conserved regions within the ybcL
ORF identified through nucleotide alignment of ybcL alleles present in
sequenced E. coli genomes. PCR was conducted using PfuDNA polymer-
ase (Stratagene), and product formation was assessed by agarose gel elec-
trophoresis. Amplicons of the predicted size were purified with the
QIAquick PCR purification kit (Qiagen) and submitted for sequencing
(SeqWright). Nucleotide alignments were performed using Vector NTI
software (Invitrogen). The prevalences of specific amino acids at position
78 in YbcL proteins from various E. coli groups were compared using
Fisher’s exact test.
Purification of YbcL variants. ybcL alleles were amplified from the
constructs described above using the following primer sets: for pYbcLUTI
and pYbcLUTI(T78V), MEL23 and MEL30; for pYbcLMG and
pYbcLMG(V78T), MEL62 andMEL30 (where the reverse primer contains a
sequence encoding a 6-histidine tag [6His] in place of the FLAG
epitope). The amplicons were cloned into pTRC99A as described above.
The constructs were confirmed by direct sequencing, and expression of
the YbcL variants was confirmed by SDS-PAGE. Periplasms were pre-
pared from E. coli Top10 carrying these plasmids and dialyzed overnight
in PBS before being applied to an Ni-nitrilotriacetic acid (NTA) column
(Qiagen). Protein purification was conducted according to the instruc-
tions of the manufacturer, using an elution buffer containing 200 mM
imidazole. Protein concentrations were determined using a bicinchoninic
acid protein assay (Thermo Scientific).
Murine cystitis and tissueMPOactivity assay.All animal procedures
were approved in advance by the Animal Studies Committee atWashing-
ton University. In accordance with a well-described model of murine
cystitis (16), 8-week-old female C3H/HeN mice (Harlan) were transure-
thrally inoculated with 50 l of bacterial suspension (2.5 107 CFU) or
sterile PBS. At 1 h postinfection (p.i.), animals were sacrificed, bladders
were harvested and homogenized in 1 ml PBS, and an aliquot of each
bladder homogenate was plated on LB agar to determine tissue bacterial
burden. The myeloperoxidase (MPO) content of bladder tissue was mea-
sured as described previously (23). Aliquots of undiluted bladder homog-
enates were transferred to a 96-well plate, and a standard curve was gen-
erated using purified MPO. Samples were incubated with the reaction
buffer for 1 h (FluoroMPO; Cell Technology) according to the manufac-
turer’s instructions. Enzyme activity was measured by fluorescent detec-
tion of an MPO product using a microplate reader (Synergy 2; BioTek).
MPO activity in the bladder samples is reported in units/ml, and data
points represent the means of triplicate measurements from individual
bladders. At least 12 mice were infected for each bacterial strain tested.
Differences in MPO levels were examined for significance using an un-
paired Student t test, and bacterial loads were compared using theMann-
Whitney U test.
RESULTS
YbcL encoded byUTI89 suppresses transepithelial PMNmigra-
tion. Given the ability of UPEC strain UTI89 to suppress innate
immune responses by undefined mechanisms (17, 18, 23), we
sought to further characterize the early host-pathogen interaction.
Guided by preliminary transcriptional profiling data (23; J.
Loughman, unpublished data), we identified a periplasmic pro-
tein, YbcL, with structural homology tomammalian Raf-1 kinase-
inhibitory protein (RKIP) (32), a modulator of eukaryotic signal
transduction pathways (22, 35, 36). To investigate a role for YbcL
in suppression of innate responses by UTI89, we utilized an in
vitromodel of acute inflammation that quantifies PMNmigration
across a bladder epithelial monolayer. Transwells bearing conflu-
ent 5637 uroepithelial monolayers were infected with E. coli
strains or mock infected for 1 h before freshly isolated human
PMN were applied to the upper reservoir, and PMN migration
into the lower reservoir was enumerated using a hemacytometer.
Consistent with our prior results (23), the nonpathogenic E. coli
UPEC YbcL Suppresses PMN Migration
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strainMG1655 stimulated robust PMNmigration, while infection
with the UPEC strain UTI89 resulted in significantly fewer PMN
in the lower reservoir (Fig. 1) (P 0.0001). The low level of PMN
migration upon UPEC infection reflects active suppression of the
inflammatory response by UPEC rather than failure to induce
inflammatory signaling, as coinfection with MG1655 plus UTI89
yields the uropathogenic phenotype (23). In contrast to wild-type
UTI89, UTI89 ybcL elicited significantly more PMN (P 
0.0001), and episomal expression of YbcL in the ybcL mutant re-
stored wild-type levels of PMNmigration (Fig. 1). The differential
PMNmigration observedwas not the result of differences in either
5637 or PMN viability; both cell types survived equally well in the
presence of the E. coli strains used at early time points, as assessed
by lactate dehydrogenase (LDH) release (data not shown). These
data suggest that YbcL encoded by UTI89 contributes to UPEC-
mediated suppression of PMNmigration.
Suppression of PMN migration by YbcLUTI relies on threo-
nine 78. To investigate the properties of YbcL responsible for
UPEC-specific suppression of the innate immune response, we
first explored sequence conservation among YbcL homologs en-
coded by E. coli. The nonpathogenic strainMG1655 (4) contains a
ybcL allele that is 95% identical at the nucleotide level to theUTI89
allele (6), resulting in six predicted amino acid differences. Four
are contained within themature protein, and three of these amino
acid differences represent conservative or semiconservative
changes (Fig. 2A and B, blue). In the single nonconservative dif-
ference, the UTI89 variant (denoted YbcLUTI) contains a threo-
nine at position 78, while theMG1655 variant (YbcLMG) contains
a valine (Fig. 2A and B, green). The crystal structure of YbcL en-
coded by K-12 strain W3110 (100% identical at the amino acid
level to YbcLMG) has been solved (32). However, any effect that
these amino acid differences may have on the tertiary structure of
YbcLUTI is unclear.
BecauseMG1655was unable to suppress in vitro PMNmigration
andYbcLcontributed to thisphenotypeduring infectionwithUTI89,
we hypothesized that the YbcL variants encoded by these E. coli
strains were functionally divergent. In accordance with this hypoth-
esis, episomal expressionof theYbcLMGvariant failed to complement
UTI89 ybcL in the transepithelial PMNmigration model (Fig. 2C)
(P  0.0001 compared to UTI89). To assess the importance of the
nonconservative amino acid substitution in suppressionof PMNmi-
gration by YbcLUTI, we generated additional YbcL variants. Expres-
sion of YbcLUTI(T78V) (containing a threonine-to-valine mutation at
position 78) in UTI89 ybcL did not suppress PMNmigration (Fig.
2C) (P 0.005), demonstrating that this mutation resulted in a loss
of function for the uropathogenic variant. Conversely, expression of
YbcLMG(V78T) (containingavaline-to-threoninemutationatposition
78) in UTI89 ybcL reduced PMN levels in the lower reservoir (Fig.
2C), demonstrating a gain of function for thenonpathogenic variant.
These data demonstrate the functional divergence of the YbcL vari-
ants encodedbynonpathogenic anduropathogenicE. coli strains and
highlight the importance of threonine 78 in YbcL for UPEC-medi-
ated suppression of PMNmigration.
Given the functional consequence of the nonconservative
amino acid difference betweenMG1655 andUTI89YbcL variants,
we hypothesized that threonine 78 would be conserved among
UPEC. We therefore assessed the distribution of YbcL homologs
among sequenced E. coli strains, focusing on the amino acid at
position 78. ABLAST search using the fullUTI89YbcL amino acid
sequence revealed YbcL homologs in many but not all sequenced
E. coli genomes, including laboratory strains, uncharacterized fe-
cal isolates, and human pathogens classified as either gastrointes-
tinal E. coli (GIPEC) (including adherent-invasive E. coli [AIEC],
enteroaggregative E. coli [EAEC], and enterohemorrhagic E. coli
[EHEC]) or extraintestinal E. coli (ExPEC) (including neonatal
meningitis E. coli [NMEC], avian-pathogenic E. coli [APEC] and
UPEC). Among the sequenced strains encoding YbcL homologs,
position 78 contained a threonine in 100% of ExPEC isolates,
compared to 39% of uncharacterized fecal isolates, 14% of GIPEC
isolates (all that contained T78 were AIEC), and 0% of laboratory
strains (Fig. 2D) (P  0.05 for ExPEC versus each group). To
further examine the correlation between threonine 78 in YbcL and
ExPEC, we amplified and sequenced ybcL alleles from clinical
UPEC isolates associatedwith a range of diseasemanifestations (6,
12, 30).Wewere unable to generate an amplicon from 26 of the 74
isolates despite using multiple primer sets, suggesting that like
sequencedE. coli strains, clinical isolates also vary in their genomic
content. Among 48 clinical isolates from which a ybcL homolog
could be amplified, 39 (81%) contained a threonine at position 78
(Fig. 2E). In total, 83% of UPEC strains (including both se-
quenced and clinical strains), compared to 25% of other E. coli
strains, encoded a threonine at position 78 (P 0.0001).
In addition to threonine and valine, alanine was also found at
position 78 in some YbcL homologs encoded by these various E.
coli strains. As with valine, episomal expression of the alanine-
containing variant YbcLUTI(T78A) failed to complement UTI89
ybcL in the transepithelial PMNmigrationmodel (Fig. 2C) (P
0.0001). Taken together, these data demonstrate the prevalence of
threonine 78 in YbcL among UPEC strains and illustrate its im-
portance in suppression of the innate immune response by these
diverse uropathogens.
YbcLUTI confers suppressive activity on nonpathogenic E.
coli MG1655. We next aimed to investigate whether other UPEC-
encoded factors were required for YbcLUTI-mediated suppression of
PMN migration. To define the bacterial context required for this
phenotype, we assessed PMNmigration in response toMG1655 ep-
isomally expressing a panel of YbcL variants. Expression of YbcLUTI
orYbcLMG(V78T) inMG1655 yieldedPMNmigration levels similar to
FIG 1 UPEC YbcL suppresses transepithelial PMN migration in vitro. 5637
bladder epithelial cell monolayers grown on Transwell inserts were infected at
their apical surfaces with the indicated strains of E. coli or mock infected, and
freshly isolated human PMN were added at the basolateral surface. The num-
ber of PMN recruited to the apical surface was enumerated at 1 h p.i. and is
shown normalized to input PMN. Infection with MG1655 or UTI89 ybcL
elicited significantly more PMN than that with wild-type UTI89 (*, P 
0.0001).
Lau et al.
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those for wild-type UTI89 (Fig. 3A), demonstrating conferral of the
uropathogenic phenotype upon the nonpathogenic strain. In con-
trast, episomal expression of YbcLMG or YbcLUTI(T78V) in MG1655
allowed significantly more PMN migration than UTI89 (Fig. 3A)
(P 0.05), consistent with the nonpathogenic phenotype.
To demonstrate that suppression of PMN migration was me-
diated directly by YbcL, we added purified YbcL protein to
MG1655 immediately before infection of the epithelial layer. An
initial concentration of 225 ng/ml was chosen to approximate the
amount of YbcL present in bacterial inocula used above that con-
tained pYbcLUTI, as determined by Western blotting (data not
shown). The addition of purified YbcLUTI or YbcLMG(V78T) upon
infection with MG1655 resulted in PMN levels similar to those
seen upon infection with UTI89 (Fig. 3B). Conversely, MG1655
plus purified YbcLMG or YbcLUTI(T78V) stimulated significantly
more PMNmigration than the uropathogenUTI89 (Fig. 3B) (P
0.01). Analogous experiments conducted using these purified
YbcL variants and UTI89 ybcL as the bacterial stimulus resulted
in the same trends in PMNmigration (data not shown). Further-
more, YbcLUTI maintained migration-suppressing potency at
concentrations as low as 150 pg/ml or 8 pM, and a decrement in
effect was observed with further dilution (Fig. 3C).
To explore whether YbcL activity required live bacteria (i.e., an
intact periplasm), we next used heat-killed MG1655 (HKMG) as
the bacterial stimulus, which elicited robust PMN migration in
contrast to UTI89 in the transepithelial PMN migration model
(Fig. 3D) (P 0.05). Infection withHKMGplus purified YbcLUTI
or YbcLMG(V78T) yielded the uropathogenic phenotype, eliciting
low levels of PMNmigration similar to those for UTI89 (Fig. 3D),
while the addition of YbcLMG or YbcLUTI(T78V) to the same bacte-
rial stimulus had no effect on PMN migration (Fig. 3D) (P 
0.005), in agreement with data generated using live MG1655.
Taken together, these data demonstrate that YbcLUTI confers the
capacity to suppress PMN migration upon nonpathogenic E. coli
and that this activity is independent of other pathogen-specific
attributes or active bacterial processes.
FIG 2 Threonine 78 is required for suppression of PMNmigration by YbcLUTI. (A and B) Amino acid alignment ofmature YbcL homologs encoded byMG1655
and UTI89 (A) and a ribbon diagram of YbcL encoded by K-12 strain W3110 (dimeric as in its crystal structure [32]) (B). Conservative and semiconservative
differences are depicted in blue, and the nonconservative difference is depicted in green. (C) Complementation of UTI89ybcL by episomal expression of YbcL
variants was assessed using an in vitromodel of transepithelial PMNmigration. Experiments were conducted and data are represented as described for Fig. 1. An
asterisk denotes a statistically significant (P 0.005) increase in PMNmigration compared to that with wild-type UTI89. (D and E) The presence of threonine
at position 78 correlates with the suppression of PMNmigration byYbcL. The distribution of amino acids at position 78 in YbcL homologs encoded by sequenced
E. coli strains (D) or clinicalUPEC isolates (E) (asymptomatic bacteriuria [ASB], acute cystitis [Acute], recurrent cystitis [Recurrent], and pyelonephritis [Pyelo])
is shown. Overall, threonine 78 is present in 83% of UPEC strains (43/52) compared to 25% of other E. coli strains (15/60) (P 0.0001).
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YbcL is secreted from the bacterial periplasm. As purified
YbcLUTI suppressed PMN migration elicited by both live and
heat-killed bacteria in the transepithelial PMN migration model,
we hypothesized that YbcLUTI was secreted from the bacterial
periplasm during UPEC infection. To demonstrate a requirement
for YbcLUTI secretion in the suppression of PMN migration by
UTI89, we engineered two fusion proteins composed of the lipo-
proteinNlpA andYbcL (36) (seeMaterials andMethods) to tether
YbcL to the inner or outer bacterial membrane (YbcLIM and
YbcLOM, respectively) and assessed the ability of these variants to
complement UTI89 ybcL in the transepithelial PMN migration
model. UTI89 ybcL episomally expressing either YbcLIM or
YbcLOM stimulated significantly more PMNmigration than wild-
type UTI89 (Fig. 4A) (P 0.005). The membrane-tethered YbcL
variants failed to complement the ybcLmutation, suggesting that
YbcLUTI does not act to suppress PMNmigration fromwithin the
bacterial periplasm.
To support these data, we sought to demonstrate secretion of
YbcLUTI by wild-typeUTI89 during infection of bladder epithelial
cells using a biochemical approach. 5637 cells in 10-cm dishes
were infected with the indicated strains of E. coli at an MOI of 40
for 1 h at 37°C. The supernatant (conditioned medium) was filter
sterilized and used in place of the bacterial inoculum in the trans-
epithelial PMNmigration model. Conditioned medium from in-
fection of 5637 cells with UTI89 stimulated a low level of PMN
migration (Fig. 4B). In contrast, conditioned medium generated
duringUTI89ybcL infection stimulated significantlymore PMN
migration (Fig. 4B) (P 0.01). This phenotype could be reversed
by expression of YbcLUTI in UTI89ybcL but not by expression of
either of the membrane-tethered YbcL variants, YbcLIM or
YbcLOM (P  0.01 compared to UTI89). These data suggest that
YbcLUTI is secreted from the bacterial periplasm and mediates
suppression of PMN migration from the exterior of the bacterial
cell.
To corroborate evidence from the transepithelial PMNmigra-
tion model suggesting that YbcLUTI is secreted, we assessed local-
ization of the YbcL variants during UPEC infection of bladder
epithelial cells or neutrophils. 5637 cells or PMN were infected
with the indicated strains of E. coli at an MOI of 40 or 10, respec-
tively, for 1 h at 37°C. The supernatant and eukaryotic cell lysate
fractions were filter sterilized, concentrated by TCA precipitation,
and resolved using SDS-PAGE. During UPEC infection of 5637
FIG 3 YbcLUTI confers suppressive activity on nonpathogenic E. coli. (A) The suppression of PMN migration by MG1655 episomally expressing the YbcL
variants was evaluated using the transepithelial PMN migration model. (B to D) This model was also used to assess changes in PMN migration caused by the
addition of purified YbcL variants to the bacterial stimulus, live MG1655 (B and C), or heat-killed MG1655 (HKMG) (D). Purified YbcL variants were added to
the bacterial stimulus immediately before infection of the epithelial layer at a final concentration of 225 ng/ml unless otherwise indicated. YbcL variants
containing a threonine at position 78, YbcLUTI and YbcLMG(V78T), suppressed PMNmigration, while YbcL variants containing a valine at this position, YbcLMG
and YbcLUTI(T78V), had no effect on PMN migration. Asterisks in panels A, B, and D indicate statistically significant (P  0.05) increases in PMN migration
compared to that with wild-type UTI89.
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cells or PMN, YbcLUTI and YbcLOM were clearly detected in the
supernatant, in contrast to YbcLIM, which wasminimally detected
in that fraction (Fig. 4C). All three YbcL variants were detected in
the PMN lysate. However, only YbcLUTI was detected in the 5637
cell lysate (Fig. 4C).When these cell typeswere infectedwith either
MG1655 or UTI89 ybcL episomally expressing the MG1655
YbcL variant, YbcLMG exhibited the same localization pattern as
YbcLUTI (data not shown), confirming that the differential PMN
migration observed in the transepithelial PMN migration model
was not the result of differences in secretion of the YbcL variants.
These data demonstrate that YbcLUTI is secreted from the bacterial
periplasm during infection of bladder epithelial cells and PMN.
Although itwas detected in the supernatant, YbcLOMdid not com-
plement the ybcL mutant in the transepithelial PMN migration
model, suggesting that localization to the supernatant is not suf-
ficient for suppression of PMNmigration by YbcLUTI.
YbcLUTI suppresses acute PMNmigration in vivo.We used a
murine model of cystitis to assess a potential contribution by
YbcLUTI to UPEC-mediated suppression of the innate response in
vivo (16, 23). Female C3H/HeN mice were transurethrally inocu-
lated with the indicated strains of E. coli or PBS, and myeloperox-
idase (MPO) activity in bladder homogenates was determined at 1
h p.i. as a surrogate for PMN influx into bladder tissue. In accor-
dance with our in vitro observations, MG1655 and UTI89 ybcL
elicited significantly more PMN than wild-type UTI89 (Fig. 5A)
(P  0.0001). Suppression of PMN migration was nearly com-
pletely restored to the ybcL mutant upon complementation with
pYbcLUTI (Fig. 5A).Modestly lower bacterial titers were recovered
after infection with the ybcL mutant or the complemented strain
compared to wild-type UTI89 (Fig. 5B) (P  0.05). It is unlikely
that these two strains exhibited a defect in colonization at this
early time point, as both assembled levels of type 1 pili similar to
those for wild-type UTI89 as assessed by microscopy, hemagglu-
tination titers, and in vitro binding and invasion assays using 5637
cells (data not shown). In addition, UTI89 ybcL formed IBCs
that were indistinguishable from those of wild-type UTI89 as as-
sessed by confocal fluorescencemicroscopy (data not shown), and
bacterial titers recovered fromwild-type- or ybcLmutant-infected
mice were similar at 6, 16, 24, and 48 hours p.i. and at 1 and 2
weeks p.i. (data not shown). In agreement with results obtained
using the in vitromodel of inflammation, these in vivo data argue
that UPEC-encoded YbcL suppresses early PMN migration in a
murine model of cystitis.
DISCUSSION
The present study identifies a novel bacterial protein encoded by
UPEC that contributes to modulation of the innate immune re-
sponse during UTI. UPEC-encoded YbcL suppressed early PMN
migration in an in vitro model of acute inflammation and an in
vivomodel of murine cystitis. Examination of the YbcL homolog
encoded by the nonpathogenic E. coli K-12 strain MG1655 re-
vealed three conservative or semiconservative andonenonconser-
vative amino acid difference compared to theUTI89 homolog.We
demonstrated that threonine at the nonconservative position 78 is
required for suppression of PMNmigration by the uropathogenic
variant YbcLUTI. In contrast, the nonpathogenic variant YbcLMG
contains a valine at this position and has no effect on PMNmigra-
tion. We hypothesize that threonine 78 is required directly or
indirectly for protein-protein interactions. Future work will in-
FIG 4 YbcLUTI is secreted. (A and B) The level of PMN migration elicited
by various strains of E. coli (A) or conditioned medium (B) was evaluated
using the transepithelial PMN migration model. YbcL variants tethered to
either the inner or outer bacterial membrane (YbcLIM or YbcLOM, respec-
tively) were unable to suppress PMNmigration when expressed episomally
in UTI89 ybcL. The trends in PMN migration observed with conditioned
medium mimicked those observed when the inoculum included live bac-
teria. Asterisks in panels A and B indicate statistically significant (P 0.05)
increases in PMN migration compared to that with wild-type UTI89. (C)
Localization of YbcL variants was assessed byWestern blotting. After 1 h of
infection of 5637 cells or PMN with the indicated strains of E. coli, the
supernatant (S) and eukaryotic cell lysate (L) fractions were filter sterilized,
TCA precipitated and resolved by SDS-PAGE. During infection of either
cell type, YbcLUTI and YbcLOM were clearly detected in the supernatant
fractions, while YbcLIM was minimally detected in those fractions. All three
variants were detected in the PMN lysate; however, only YbcLUTI was de-
tected in the 5637 cell lysate. An equivalent volume of each bacterial inoc-
ulum (I) is shown for comparison across strains.
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vestigate how the identity of a single amino acid dictates YbcL
functionality in this model of transepithelial PMN migration.
The presence of YbcL homologs in many but not all E. coli
strains exemplifies both the genomic heterogeneitywithin the spe-
cies and the variation in mechanisms of immune modulation
among pathogenic strains. We were not surprised to find YbcL
homologs containing threonine 78 in some uncharacterized fecal
isolates and GIPEC strains, as the GI tract serves as a reservoir for
UPEC in addition to the resident (commensal) microflora and
supports a considerable amount of horizontal gene transfer. Like
UPEC in the urinary tract, GIPEC influences local immune re-
sponses within the GI tract (7), although it is unclear if YbcL
homologs contribute to this phenotype in the gut. Given that the
majority of GIPEC strains encode valine- or alanine-containing
YbcL homologs, immune modulation in the GI tract by these
strains more likely occurs independently of YbcL. In contrast, the
prevalence of threonine 78 among UPEC-encoded YbcL ho-
mologs suggests that suppression of PMNmigration by YbcL is a
conserved mechanism of innate immune modulation within the
urinary tract. As threonine-containingYbcLhomologs are present
in UPEC strains that cause asymptomatic bacteriuria and pyelo-
nephritis in addition to acute and recurrent cystitis, it is likely that
YbcL contributes to pathogenesis throughout the urinary tract.
Using a murine cystitis model, we demonstrated that YbcL en-
coded by UTI89 suppresses acute PMN migration to the bladder.
Compared to wild-type UTI89, both the ybcLmutant and the com-
plemented strain yieldedmodestly lower bacterial titers at 1 h p.i.We
hypothesize that the lower ybcL mutant titers may be the result of
increased PMN recruitment to those bladders, as evidenced by ele-
vatedMPO levels. In agreement with that hypothesis,MG1655 titers
also trended lower thanUTI89 titers at 1hp.i.The slightly lower titers
in the complement-infected bladders might relate to decreased bac-
terial fitness causedbymaintenance of the plasmidor overexpression
of YbcLUTI, as PMN levels were similar to those measured in wild-
type infection. Examination of IBC formation and bacterial titers at
subsequent time points revealed no significant differences between
wild-type- and ybcL-infected mice, suggesting that YbcL facilitates
the establishment of UTI rather than persistence. Considering the
large bacterial inoculum (107 CFU) and the capacity of IBCs to
amplify and propagate infection, it is not surprising that increased
PMNrecruitment in theUTI89ybcL-infectedbladders earlydidnot
adversely affect bacterial titers at later time points. In the human uri-
nary tract, where the inoculum is likely to be significantly lower and
varying host genetics influence susceptibility to UTI, the activity of
YbcLUTI may significantly favor bacterial survival prior to epithelial
invasion, tipping the balance toward infection rather than clearance.
Suppression of PMN migration by YbcLUTI was conferred by
episomal expression or the addition of purified protein to either
live or nonviable MG1655, demonstrating that YbcLUTI functions
independently of bacterial context.Usingmultiple approaches, we
demonstrated that YbcL was secreted by UTI89 during infection
of bladder epithelial cells or PMN. We were unable to detect
YbcLUTI byWestern blotting in filter-sterilized, TCA-precipitated
conditioned medium from UTI89/pYbcLUTI ybcL grown in LB
(M. Lau and D. Hunstad, unpublished data), suggesting that se-
cretion of YbcLUTI is regulated. Given that the localization pattern
of YbcLMG mimicked the pattern of YbcLUTI during infection of
eukaryotic cells, it is unlikely that the amino acid at position 78
regulates secretion. While YbcL was detected in the supernatant,
the mode of delivery from the bacterial cell remains unclear, al-
though it is unlikely to be pathogen specific, as the localization
pattern of the YbcL variants (YbcLUTI and YbcLMG) was indepen-
dent of the bacterial strain, MG1655 or UTI89 ybcL. In light of
these observations, we hypothesize that secretion of YbcLUTI, a
periplasmic protein, occurs through outer membrane proteins
(such as secretins) or via outermembrane vesicles (OMVs). Given
its presence in the bacterial outer membrane, we hypothesize that
YbcLOM in the supernatant fraction during UPEC infection is as-
sociated with OMVs and that the membrane tether prevents that
YbcL variant from suppressing PMN migration. As periplasmic
proteins as well as outer membrane proteins are packaged in
OMVs and precedent exists for the delivery of UPEC effectors via
OMVs (e.g., cytotoxic necrotizing factor 1) (9), it is possible that
these vesiclesmediate YbcLUTI secretion. Future work will address
these hypotheses.
In addition to localization to the supernatant during UPEC
infection, similar levels of the three YbcL variants were also de-
tected in the filtered PMN lysate. It is unlikely that the PMN-
associated YbcL signal originated from internalization of super-
natant YbcL, as YbcLIMwas not present in the supernatant butwas
detected in the PMN lysate. Rather, as PMN are professional
phagocytes, we hypothesize that the PMN-associated YbcL signal
was generated via bacterial lysis within the phagolysosome. In ad-
FIG 5 YbcLUTI suppresses acute PMNmigration in vivo. C3H/HeNmice were
infected with the indicated strains of E. coli or PBS, and bladders were har-
vested at 1 h p.i. (A) A surrogate for PMN infiltration in the bladder, myelo-
peroxidase (MPO) activity, was measured in bladder homogenates by fluores-
cent detection of anMPOproduct and is represented in units/ml.MG1655 and
UTI89 ybcL elicited significantly more PMN than wild-type UTI89 (*, P 
0.0001). (B) Bladders infected with UTI89 ybcL or the complemented strain
showed a small but statistically significant decrease in bacterial load compared
to those infectedwithUTI89 (*, P 0.05). Horizontal lines indicate themeans
in both panels.
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dition to the supernatant and PMN lysate, YbcLUTI also was de-
tected in the 5637 cell lysate. As the membrane-tethered YbcL
variants were not 5637 cell associated and were unable to comple-
ment the ybcL mutant in the transepithelial PMN migration
model, it is possible that association with epithelial cells is re-
quired for suppression of PMNmigration by YbcLUTI. Future ex-
perimentation will focus on specifying the relative contribution of
YbcL activity on these cell types to the suppression of PMN mi-
gration in our models.
Elucidation of the YbcL crystal structure by Serre and col-
leagues revealed structural homology to the mammalian protein
RKIP (32), which modulates signal transduction pathways, in-
cluding the mitogen-activated protein (MAP) kinase and NF-B
pathways (35, 36). Klumpp and colleagues demonstrated that
UPEC strainNU14 inhibits signaling through theMAPkinase and
NF-B pathways during in vitro infection of cultured bladder ep-
ithelial cells (20), although themechanism underlying this inhibi-
tion remains unclear. Like NU14, UTI89 also inhibits signaling
through these pathways, though this occurs independent of
YbcLUTI (M. Lau and D. Hunstad, unpublished data), demon-
strating that YbcLUTI and RKIP have distinct functions despite
their structural homology. Furthermore, UTI89 ybcL, like wild-
type UTI89, elicits minimal interleukin-6 (IL-6) and IL-8 from
cultured bladder epithelial cells or human PMN relative to that
elicited by MG1655 (Lau and Hunstad, unpublished data), sug-
gesting that differences in the induction of these cytokines are
not responsible for the increased PMN migration observed
with ybcL deletion. Given the structural homology between
YbcL and RKIP, the low concentration of YbcLUTI required to
suppress PMN migration, and the presence of YbcLUTI in eu-
karyotic cell lysates, we hypothesize that YbcLUTI inhibits a
eukaryotic signaling cascade that promotes transepithelial
PMN migration. Ongoing work aims to elucidate the mecha-
nism underlying the differential PMN migration and the role
that YbcLUTI plays in mediating this phenotype, with specific
attention to the importance of threonine 78.
The success of many mucosal pathogens relies on strategies to
modulate host immune processes at the epithelial interface. By
suppressing acute PMN recruitment, YbcL may extend the win-
dow inwhichUPEC can accomplish epithelial invasion and estab-
lish the protected intracellular niche required for propagating in-
fection. YbcL represents a novel example of a bacterial exoprotein
that influences early host-pathogen interactions within the uri-
nary tract.
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